Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Stifel Financial Corp

Stifel Financial Corp trimmed its holdings in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 32.4% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 41,917 shares of the company's stock after selling 20,062 shares during the quarter. Stifel Financial Corp's holdings in Moderna were worth $2,801,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Assenagon Asset Management S.A. increased its holdings in shares of Moderna by 13.0% in the second quarter. Assenagon Asset Management S.A. now owns 7,352 shares of the company's stock worth $873,000 after purchasing an additional 843 shares during the last quarter. Fifth Third Bancorp increased its stake in Moderna by 19.7% in the 2nd quarter. Fifth Third Bancorp now owns 11,178 shares of the company's stock worth $1,327,000 after acquiring an additional 1,842 shares during the last quarter. Atria Wealth Solutions Inc. raised its holdings in shares of Moderna by 273.2% during the 2nd quarter. Atria Wealth Solutions Inc. now owns 27,408 shares of the company's stock worth $3,255,000 after acquiring an additional 20,064 shares in the last quarter. Premier Path Wealth Partners LLC bought a new position in shares of Moderna during the 2nd quarter valued at approximately $283,000. Finally, Everhart Financial Group Inc. purchased a new position in shares of Moderna in the second quarter valued at $274,000. 75.33% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have commented on MRNA. The Goldman Sachs Group lowered their price objective on shares of Moderna from $178.00 to $139.00 and set a "buy" rating for the company in a research report on Monday, September 16th. UBS Group decreased their target price on shares of Moderna from $140.00 to $108.00 and set a "buy" rating on the stock in a research report on Thursday, October 24th. Royal Bank of Canada reiterated a "sector perform" rating and issued a $75.00 price target on shares of Moderna in a research report on Thursday, September 19th. Sanford C. Bernstein started coverage on Moderna in a research report on Thursday, October 17th. They set a "market perform" rating and a $55.00 price objective on the stock. Finally, Wolfe Research started coverage on Moderna in a research note on Friday, November 15th. They issued an "underperform" rating and a $40.00 price objective for the company. Four analysts have rated the stock with a sell rating, twelve have given a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Hold" and an average price target of $79.50.

Moderna Trading Up 3.1 %

Shares of NASDAQ:MRNA traded up $1.20 during trading on Thursday, reaching $39.56. 7,489,352 shares of the company were exchanged, compared to its average volume of 5,020,101. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. The firm has a market capitalization of $15.22 billion, a PE ratio of -6.80 and a beta of 1.58. The business's fifty day simple moving average is $47.16 and its 200-day simple moving average is $81.43. Moderna, Inc. has a 12-month low of $35.80 and a 12-month high of $170.47.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($1.89) by $1.92. The business had revenue of $1.90 billion during the quarter, compared to analysts' expectations of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The business's revenue for the quarter was up 3.8% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.39) EPS. On average, research analysts anticipate that Moderna, Inc. will post -9.3 EPS for the current year.

Insider Activity at Moderna

In other news, insider Shannon Thyme Klinger sold 1,418 shares of Moderna stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $60,676.22. Following the transaction, the insider now owns 19,717 shares of the company's stock, valued at $843,690.43. The trade was a 6.71 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO James M. Mock sold 715 shares of the stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the sale, the chief financial officer now directly owns 9,505 shares of the company's stock, valued at $571,440.60. The trade was a 7.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 3,379 shares of company stock valued at $158,195 over the last ninety days. 15.20% of the stock is owned by company insiders.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.